Atherogenic Lipid Profile and Hepatic Enzyme Alterations in Metabolic Syndrome: A Case-Control Study in a South Indian Population

Authors

  • Dr. Siva Adarsh Author

DOI:

https://doi.org/10.48047/

Keywords:

Metabolic syndrome; Lipid profile; Liver enzymes; AST/ALT ratio; Non-alcoholic fatty liver disease; Atherogenic index; Hepatic insulin resistance.

Abstract

Background: Metabolic syndrome (MetS) is a cluster of interrelated cardiometabolic risk factors — central obesity, dyslipidaemia, hypertension, and dysglycaemia — that collectively predispose to type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD).  The hepatic component of MetS is increasingly recognized

Downloads

Download data is not yet available.

References

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the IDF Task Force on Epidemiology and Prevention. Circulation. 2009;120(16):1640-5.

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):141528.

Downloads

Published

2017-04-20

Issue

Section

Articles

How to Cite

Dr. Siva Adarsh. (2017). Atherogenic Lipid Profile and Hepatic Enzyme Alterations in Metabolic Syndrome: A Case-Control Study in a South Indian Population . History of Medicine, 4(4), 413-423. https://doi.org/10.48047/